Cantor Fitzgerald analyst Louise Chen maintained a Buy rating on Paratek Pharmaceuticals (NASDAQ: PRTK) today and set a price target of $50. The company’s shares opened today at $8.85, close to its 52-week low of $8.47.
Chen said:
“We rate PRTK’s stock as 12-month price target of $50. We expect upwards earnings revisions for Nuzyra and Seysara sales to levels not reflected in consensus expectations to drive PRTK shares higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) to get to our 12-month price target of $50. The Disclosure Section may be found on pages 3 – 4.Valuation We use a blend of DCF and multiples (EV/EBITDA) to get to our 12-month price target of $50.”
According to TipRanks.com, Chen is a 5-star analyst with an average return of 11.7% and a 40.6% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Aridis Pharmaceuticals Inc, and Melinta Therapeutics Inc.
Currently, the analyst consensus on Paratek Pharmaceuticals is a Strong Buy with an average price target of $32.80.
See today’s analyst top recommended stocks >>
The company has a one-year high of $23 and a one-year low of $8.47. Currently, Paratek Pharmaceuticals has an average volume of 781.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Paratek Pharmaceuticals, Inc. engages in the development and commercialization of therapies based upon tetracycline chemistry. Its products include Omadacycline and Sarecycline, which are used for the treatment of serious community-acquired bacterial infections, including community-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, and urinary tract infections. The company was founded in February 2001 and is headquartered in Boston, MA.
